BR112013028751A2 - processo para a fabricação de etexilato de dabigatrana e intermediários do mesmo - Google Patents

processo para a fabricação de etexilato de dabigatrana e intermediários do mesmo

Info

Publication number
BR112013028751A2
BR112013028751A2 BR112013028751A BR112013028751A BR112013028751A2 BR 112013028751 A2 BR112013028751 A2 BR 112013028751A2 BR 112013028751 A BR112013028751 A BR 112013028751A BR 112013028751 A BR112013028751 A BR 112013028751A BR 112013028751 A2 BR112013028751 A2 BR 112013028751A2
Authority
BR
Brazil
Prior art keywords
intermediates
manufacture
dabigatran etexilate
dabigatran
dabigatran etexylate
Prior art date
Application number
BR112013028751A
Other languages
English (en)
Inventor
András Boza
Balázs Volk
Gyula Lukács
Gyula Simig
György Ruzsics
Imre Király
József Barkóczy
László Pongó
László Szlávik
Mária Kovács
Mária Tóthné Lauritz
Tibor Szab
Original Assignee
Egis Gyógyszergyár Nyilvánosan Muködo Részvénytársaság
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egis Gyógyszergyár Nyilvánosan Muködo Részvénytársaság filed Critical Egis Gyógyszergyár Nyilvánosan Muködo Részvénytársaság
Publication of BR112013028751A2 publication Critical patent/BR112013028751A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

resumo patente de invenção: "processo para a fabricação de etexilato de dabigatrana e intermediários do mesmo". a presente invenção refere-se a um processo para a preparação de etexilato de dabigatrana da fórmula (i) ou sais farmaceuticamente aceitáveis dos mesmos.
BR112013028751A 2011-05-11 2012-05-10 processo para a fabricação de etexilato de dabigatrana e intermediários do mesmo BR112013028751A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU1100244A HUP1100244A2 (hu) 2011-05-11 2011-05-11 Gyógyszeripari intermedierek és eljárás elõállításukra
PCT/HU2012/000036 WO2012153158A1 (en) 2011-05-11 2012-05-10 Process for the manufacture of dabigatran etexilate and intermediates thereof

Publications (1)

Publication Number Publication Date
BR112013028751A2 true BR112013028751A2 (pt) 2016-08-09

Family

ID=89990279

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013028751A BR112013028751A2 (pt) 2011-05-11 2012-05-10 processo para a fabricação de etexilato de dabigatrana e intermediários do mesmo

Country Status (6)

Country Link
US (1) US9260421B2 (pt)
EP (1) EP2707364B1 (pt)
CN (1) CN103619832A (pt)
BR (1) BR112013028751A2 (pt)
HU (2) HUP1100244A2 (pt)
WO (1) WO2012153158A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2013CH03939A (pt) * 2013-09-03 2015-09-11 Laurus Labs Pvt Ltd
IN2014MU00675A (pt) 2014-02-26 2015-10-23 Megafine Pharma P Ltd
CN103896919A (zh) * 2014-04-21 2014-07-02 南京靖龙药物研发有限公司 一种氘代达比加群的制备方法
CN104628714B (zh) * 2015-02-04 2018-02-16 沈阳工业大学 达比加群的酯衍生物及其制备方法和用途
CN105646531B (zh) * 2016-03-28 2017-11-21 沈阳工业大学 达比加群环状衍生物及其制备方法和用途
CN111060452B (zh) * 2019-12-23 2022-08-05 山西斯珂炜瑞光电科技有限公司 一种补偿古依相移增加非线性相互作用的晶体炉装置
CN111334537A (zh) * 2020-04-01 2020-06-26 中山万汉制药有限公司 酶催化的达比加群酯中间体的合成方法
CN114113346B (zh) * 2020-08-25 2024-01-12 石药集团恩必普药业有限公司 一种达比加群酯原料药或制剂中对甲苯磺酸乙酯、对甲苯磺酸异丙酯的检测方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
ZA988735B (en) * 1997-10-06 2000-03-23 Du Pont Pharm Co An efficient method for the conversion of nitriles to amidines.
US6248770B1 (en) * 1998-07-09 2001-06-19 Boehringer Ingelheim Pharma Kg Benzimidazoles having antithrombotic activity
EP1612220A3 (en) 1999-03-23 2006-02-15 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6451832B2 (en) * 1999-12-23 2002-09-17 Boehringer Ingelheim Pharma Kg Benzimidazoles with antithrombotic activity
EP1621220B1 (en) 2003-05-08 2014-11-19 Kaneka Corporation Low density lipoprotein/fibrinogen adsorbent and adsorption apparatus capable of whole blood treatment
DE10339862A1 (de) 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
EP1609784A1 (de) 2004-06-25 2005-12-28 Boehringer Ingelheim Pharma GmbH & Co.KG Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen
DE102005025728A1 (de) 2005-06-04 2006-12-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-Propionsäure-ethylester
US7782189B2 (en) 2005-06-20 2010-08-24 Carestream Health, Inc. System to monitor the ingestion of medicines
ITTO20050486A1 (it) 2005-07-14 2005-10-13 Dumitru Bucuresteanu Compressore ad aria funzionante a elica continua in un tubo girevole
UY29896A1 (es) 2005-11-04 2007-06-29 Astrazeneca Ab Nuevos derivados de cromano, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
FR2894963A1 (fr) 2005-12-16 2007-06-22 Inst Nat Sante Rech Med Nouveaux composes interagissant avec pea-15
DE102005061623A1 (de) 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verbessertes Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen und deren Salzen
DE102006054005A1 (de) 2006-11-16 2008-05-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
CZ305085B6 (cs) * 2008-03-14 2015-04-29 Zentiva, K.S. Způsob přípravy dabigatranu
EP2300431B1 (en) 2008-06-16 2016-01-06 Boehringer Ingelheim International GmbH Process for the manufacture of an intermediate in the synthesis of dabigatran
AU2009259440B2 (en) 2008-06-16 2014-05-29 Boehringer Ingelheim International Gmbh Method for producing an intermediate product of dabigatran etexilate
CZ2008669A3 (cs) 2008-10-24 2010-05-05 Zentiva, A. S. Zpusob prípravy dabigatranu a jeho meziprodukty
WO2012077136A2 (en) 2010-12-06 2012-06-14 Msn Laboratories Limited Process for the preparation of benzimidazole derivatives and its salts

Also Published As

Publication number Publication date
EP2707364A1 (en) 2014-03-19
US9260421B2 (en) 2016-02-16
EP2707364B1 (en) 2016-08-24
CN103619832A (zh) 2014-03-05
US20140155614A1 (en) 2014-06-05
WO2012153158A1 (en) 2012-11-15
HUP1100244A2 (hu) 2012-11-28
HUE030696T2 (en) 2017-05-29

Similar Documents

Publication Publication Date Title
BR112013028751A2 (pt) processo para a fabricação de etexilato de dabigatrana e intermediários do mesmo
CY1122498T1 (el) Δευτεριωμενα παραγωγα ιβακαφτορης
BR112014003079A2 (pt) derivado de 1,2,3,4-tetra-hidroquinolina útil para o tratamento de diabetes
BR112015017997A2 (pt) amidas de quinolina e quinazolina como moduladores de canais de sódio
BR112013000920A2 (pt) compostos para a redução de produção de beta-amiloide
BR112012017402A2 (pt) inibidores de vírus de flaviviridae
UY32174A (es) Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones
EA201290726A1 (ru) Новые соли для получения фармацевтических композиций
EA201590975A1 (ru) Ингибиторы prmt5 и их применение
EA201490949A1 (ru) Ингибиторы киназ
BR112014008807A2 (pt) compostos de tetra-hidroisoquinolina substituídos como inibidores do fator xia
BR112014010420A2 (pt) inibidores de pak para o tratamento de distúrbios proliferativos celulares
BR112013029537A2 (pt) derivados de quinazolina para tratamento de infecções virais e outras doenças
BR112014003225A2 (pt) profármacos de treprostinil ligados a veículo
BR112014009717A8 (pt) derivados de 2-(fenil ou pirid-3-il)aminopirimidina como moduladores de cinase lrrk2 para o tratamento de doença de parkinson.
BR112014010401A8 (pt) Inibidores do vírus da hepatite c rod-like que contêm o fragmento {2-[4-(bifenil-4-il)-1h-imidazo-2-il] pirrolidina-1-carbonilmetil}amina
BR112014014452A2 (pt) derivados de pirazolpiridina, processo de preparação dos mesmos e uso terapêutico dos mesmos
BR112014013108A2 (pt) compostos tricíclicos fundidos como inibidores da quinase raf
BR112013019256A2 (pt) inibição de il-17 e ifn-gama para o tratamento de inflamação autoimune
BR112013020536A2 (pt) 1,4-oxazepinas como inibidores de bace1 e/ou bace2
BR112013029730A2 (pt) composição farmacêutica de rosuvastatina cálcica
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
BR112015002275A2 (pt) processos e intermediários para a preparação de inibidores da integrase
BR112013017362A2 (pt) composto de fórmula (i), processo para preparar um composto de fórmula (i), composição farmacêutica e compostos, métodos e usos inovadores
BR112013017968A2 (pt) processo para fazer inibidores de girase e de topoisomerase

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]